These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16352726)

  • 1. Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity.
    Wang F; Habtemariam A; van der Geer EP; Fernández R; Melchart M; Deeth RJ; Aird R; Guichard S; Fabbiani FP; Lozano-Casal P; Oswald ID; Jodrell DI; Parsons S; Sadler PJ
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18269-74. PubMed ID: 16352726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
    Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
    J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
    Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
    Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, characterization, and reaction pathways for the formation of a GMP adduct of a cytotoxic thiocyanato ruthenium arene complex.
    Wang F; Habtemariam A; van der Geer EP; Deeth RJ; Gould R; Parsons S; Sadler PJ
    J Biol Inorg Chem; 2009 Sep; 14(7):1065-76. PubMed ID: 19499253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
    Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
    J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.
    Chen H; Parkinson JA; Morris RE; Sadler PJ
    J Am Chem Soc; 2003 Jan; 125(1):173-86. PubMed ID: 12515520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
    Peacock AF; Parsons S; Sadler PJ
    J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.
    Chen H; Parkinson JA; Parsons S; Coxall RA; Gould RO; Sadler PJ
    J Am Chem Soc; 2002 Mar; 124(12):3064-82. PubMed ID: 11902898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cancer cell growth by ruthenium(II) arene complexes.
    Morris RE; Aird RE; Murdoch Pdel S; Chen H; Cummings J; Hughes ND; Parsons S; Parkin A; Boyd G; Jodrell DI; Sadler PJ
    J Med Chem; 2001 Oct; 44(22):3616-21. PubMed ID: 11606126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
    Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
    Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
    Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
    Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
    Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
    J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
    Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
    Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
    van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
    Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cysteine thiols on the catalytic and anticancer activity of Ru(II) sulfonyl-ethylenediamine complexes.
    Chen F; Romero-Canelón I; Habtemariam A; Song JI; Banerjee S; Clarkson GJ; Song L; Prokes I; Sadler PJ
    Dalton Trans; 2022 Mar; 51(11):4447-4457. PubMed ID: 35226015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New water-soluble ruthenium(II) terpyridine complexes for anticancer activity: synthesis, characterization, activation kinetics, and interaction with guanine derivatives.
    Rilak A; Bratsos I; Zangrando E; Kljun J; Turel I; Bugarčić ŽD; Alessio E
    Inorg Chem; 2014 Jun; 53(12):6113-26. PubMed ID: 24884156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of Ru-arene Complexes for Antitumor Drugs.
    Su W; Li Y; Li P
    Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Application of Reversible Intramolecular Sulfonamide Ligation to Modulate Reactivity in Organometallic Ruthenium(II) Diamine Complexes.
    Kemp SA; Prior TJ; Savoie H; Boyle RW; Murray BS
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31936104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships for organometallic osmium arene phenylazopyridine complexes with potent anticancer activity.
    Fu Y; Habtemariam A; Basri AM; Braddick D; Clarkson GJ; Sadler PJ
    Dalton Trans; 2011 Oct; 40(40):10553-62. PubMed ID: 21860862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catalysis of regioselective reduction of NAD+ by ruthenium(II) arene complexes under biologically relevant conditions.
    Yan YK; Melchart M; Habtemariam A; Peacock AF; Sadler PJ
    J Biol Inorg Chem; 2006 Jun; 11(4):483-8. PubMed ID: 16604356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.